Curonix announced the Curonix CFO appointment of Russell Fleeger, effective immediately. The Curonix Chief Financial Officer (CFO) move reinforces its growth strategy in neurostimulation and PNS therapy. Moreover, the company highlighted his global finance expertise and medical device background.
Fleeger brings more than 25 years of experience to Curonix. Notably, he served as Chief Financial Officer (CFO) of Franklin Electric’s largest segment. Previously, he held senior roles at Biomet and Zimmer Biomet across finance and commercial leadership. In addition, he led Asia Pacific strategy and integration for several years.
Curonix develops therapies that relieve chronic pain through peripheral nerve stimulation. Therefore, leadership with deep operational rigor matters for scaling access and outcomes. The Curonix CFO will help drive capital allocation, forecasting, and operational excellence. Furthermore, he will support expansion for its neurostimulation business model and PNS therapy.
According to the announcement, Fleeger holds an MBA from Indiana University. He also earned a BA in Economics from Valparaiso University. Moreover, through the various pitches, he constantly pointed out the main objective of Curonix. It was to change the way chronic pain is treated. He is looking forward to working closely with the executive team to set up operations efficiently. Also, wants to ensure a rapid growth journey in the key markets.
It would mean that as the company grows, the role of governance and finance discipline will become more important. As a result, the Curonix CFO position is in line with the company’s strategic growth and commercial activities. The announcement of this appointment, therefore, acts as a lever to strengthen leadership for data-driven healthcare and market development. It is all about the company positioning itself for the future in medical technology.
For more stories on executive leadership and business innovations, explore our CXO Insiders for the latest updates.
Source: GlobeNewswire
